- Home
- TBRG vs TNGX Comparison
TBRG vs TNGX Comparison
Compare TBRG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- TNGX
- Stock Information
- Founded
- TBRG 1979
- TNGX 2014
- Country
- TBRG United States
- TNGX United States
- Employees
- TBRG N/A
- TNGX N/A
- Industry
- TBRG
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TBRG
- TNGX Health Care
- Exchange
- TBRG NYSE
- TNGX Nasdaq
- Market Cap
- TBRG 393.0M
- TNGX 351.2M
- IPO Year
- TBRG N/A
- TNGX N/A
- Fundamental
- Price
- TBRG $23.21
- TNGX $4.93
- Analyst Decision
- TBRG Buy
- TNGX Strong Buy
- Analyst Count
- TBRG 3
- TNGX 6
- Target Price
- TBRG $23.67
- TNGX $12.20
- AVG Volume (30 Days)
- TBRG 209.7K
- TNGX 4.0M
- Earning Date
- TBRG 08-07-2025
- TNGX 08-06-2025
- Dividend Yield
- TBRG N/A
- TNGX N/A
- EPS Growth
- TBRG N/A
- TNGX N/A
- EPS
- TBRG N/A
- TNGX N/A
- Revenue
- TBRG $345,737,000.00
- TNGX $40,990,000.00
- Revenue This Year
- TBRG $5.15
- TNGX N/A
- Revenue Next Year
- TBRG $5.25
- TNGX N/A
- P/E Ratio
- TBRG N/A
- TNGX N/A
- Revenue Growth
- TBRG 3.56
- TNGX 10.09
- 52 Week Low
- TBRG $9.75
- TNGX $1.03
- 52 Week High
- TBRG $32.00
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- TBRG 48.92
- TNGX 69.44
- Support Level
- TBRG $22.10
- TNGX $4.70
- Resistance Level
- TBRG $23.49
- TNGX $5.63
- Average True Range (ATR)
- TBRG 0.78
- TNGX 0.60
- MACD
- TBRG 0.02
- TNGX -0.01
- Stochastic Oscillator
- TBRG 54.67
- TNGX 65.38
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are Revenue Cycle Management (RCM), (ii) Electronic Health Records (EHR), and (iii) Patient Engagement The company derives maximum revenue from the RCM segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.